For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Larazotide
Illustration for Larazotide

THE PEPSRADAR ENCYCLOPEDIA

Larazotide

Celiac disease symptom research

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Larazotide · KEY FACTS

Content updated · how dates work

Saved peptides

What is Larazotide?

Larazotide is an investigational peptide studied for persistent symptoms in celiac disease. The featured trial kept participants on a gluten-free diet.

Biological role or research focus

Celiac disease symptom research.

A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.

Role reference: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Names you may encounter

Larazotide acetate

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Investigational tight-junction regulator peptide
Research focus
Celiac disease symptom research
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Quick answers

Is Larazotide FDA approved?
No. No FDA-approved drug contains Larazotide. Source ↗
Is Larazotide safe?
Larazotide is an investigational celiac-disease peptide. Trials found side effects similar to placebo over a few months, but it is not approved and long-term safety is unknown. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Larazotide banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Larazotide celiac-disease phase 2 trial (2015)Human randomized trial342 adults with celiac disease and persistent symptoms after at least 12 months on a gluten-free diet.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2015

Larazotide celiac-disease phase 2 trial

Did persistent celiac symptoms improve while participants maintained a gluten-free diet?

Population / model
342 adults with celiac disease and persistent symptoms after at least 12 months on a gluten-free diet.
Study design
Randomized double-blind placebo-controlled 12-week trial with run-in and follow-up periods; three active-treatment groups.
Main finding
One active-treatment group met the primary symptom endpoint; the other two did not show improvement on that endpoint. Safety was comparable with placebo during the trial.
Limits & context
A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

10 registered studies name Larazotide as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 8 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
AT1001 for the Treatment of Long COVID
NCT05747534 · Massachusetts General Hospital
CompletedPhase 22023-05-31107
AT1001 for the Treatment of COVID-19 Related MIS-C
NCT05022303 · Massachusetts General Hospital
TerminatedPhase 22021-10-0112
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
NCT03569007 · 9 Meters Biopharma, Inc.
TerminatedPhase 32019-05-29307
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
NCT01396213 · 9 Meters Biopharma, Inc.
CompletedPhase 22011-11-07342
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
NCT00889473 · 9 Meters Biopharma, Inc.
CompletedPhase 22009-0442
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
NCT00620451 · 9 Meters Biopharma, Inc.
CompletedPhase 22008-02105
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
NCT00492960 · 9 Meters Biopharma, Inc.
CompletedPhase 22007-08171
Safety of Larazotide Acetate in Healthy Volunteers
NCT00386490 · 9 Meters Biopharma, Inc.
CompletedPhase 12006-01-1024

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 10 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection. ↗
European heart journal · 2023 Apr 7 · Journal Article, Research Support, Non-U.S. Gov't

Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. ↗
Nature communications · 2020 Apr 24 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments. ↗
Nutrients · 2025 Sep 15 · Journal Article, Review
Read available full text ↗

Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration. ↗
Gut · 2026 Mar 6 · Journal Article, Review

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Larazotide is an investigational celiac-disease peptide. Trials found side effects similar to placebo over a few months, but it is not approved and long-term safety is unknown.

Human safety data: Trials only

Phase 2 trials, including one with 342 adults, and a meta-analysis report it was generally well tolerated over weeks to months. Longer exposure and use outside celiac disease have not been studied for safety.

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Larazotide for persistent celiac symptoms: randomized trial (2015) ↗ · Larazotide in celiac disease: meta-analysis (2022) ↗

What the featured evidence can tell us

Comparable short-term adverse-event rates do not establish long-term safety or benefit in people without celiac disease.

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Identity, route, and evidence limits

A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical context & research status

The study examined adults with celiac disease and persistent symptoms despite a gluten-free diet. It did not test replacing that diet or unrestricted gluten intake.

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.

No verified matching catalog listing yet

We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.

How Larazotide works

The proposed approach concerns regulation of intestinal tight junctions. A barrier-related hypothesis is not proof of a general treatment for conditions described as “leaky gut.”

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Molecular structure

Larazotide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 9810532 ↗

Questions worth asking

  • Could larazotide replace a gluten-free diet?
  • What population, comparator, and route were actually studied?
  • A nonuniform response across groups makes simple dose-response claims inappropriate. Symptom scores are different from demonstrating prevention of long-term complications.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Could larazotide replace a gluten-free diet?

This trial maintained the gluten-free diet. Its findings cannot establish that larazotide makes gluten exposure safe.

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. · 2015 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Larazotide

Download illustration ↓Source record ↗
Larazotide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.